Many other studies have since demonstrated the therapeutic efficacy of KCa3.1 inhibition in other models of neurological injury and disease in which microglia are believed to play a significant role, including experimental autoimmune encephalomyelitis, traumatic brain injury, spinal cord injury, optic nerve transection, glioblastoma multiforme, neuropathic pain, and AD (Dale et al., 2016; Staal et al., 2017b). The gene discussed is KCNN4; the disease is Alzheimer disease.